Pretreatment characteristics of chronic myelogenous leukemia patients
| Patient no. . | Age, y . | Sex . | Disease duration, y . | IFN status . | Karyotype [no. metaphases] . |
|---|---|---|---|---|---|
| 1 | 46 | F | 4.1 | Resistant | 46,XX, t(22;9)(9;1)(q11;q34-q32;q42) [18] |
| 2 | 19 | F | 3.7 | Resistant | 46,XX, t(9;22)(q34;q11)[17]/ 46,XX [9] |
| 3 | 54 | F | 1.6 | Intolerant | 46,XX, t(9;22)(q34;q11) [20] |
| 4 | 66 | M | 2.5 | Intolerant | 46,XY, t(9;22)(q34;q11) [20] |
| 5 | 60 | F | 4.2 | Resistant | 46,XX, t(9;22)(q34;q11) [19]/ 46,XX [1] |
| 6 | 51 | F | 1.8 | Intolerant | 46,XX, t(9;22)(q34;q11) [17]/ 46,XX [3] |
| 7 | 69 | M | 3.9 | Resistant | 46,XY, t(9;22)(q34;q11) [21] |
| 8 | 65 | M | 7.3 | Resistant | 46,XY, t(9;22)(q34;q11) [15] |
| 9 | 70 | M | 6.5 | Intolerant | 46,XY, t(9;22)(q34;q11)[23]/ 46XY [2] |
| 10 | 60 | F | 1.7 | Resistant | 46,XX, t(7;8)(q22;q13), t(9;22)(q34;q11) [15]/ 46,XX, t(9;22)(q34;q11) [5]/ 46,XX [1] |
| 11 | 52 | M | 1.1 | Resistant/Intolerant | 46,XY, t(9;22)(q34;q11) [21] |
| 12 | 64 | M | 3.9 | Resistant | 46,XY, t(22;9)(9;13;1)(q11;q34;q32;q21;q31) [19]/ 47,XY, t(22;9)(9;13;1)(q11;q34;q32;q21;q31),+ 8 [1] |
| 13 | 69 | F | 1.5 | Resistant | 46,XX, t(9;22)(q34;q11) [20] |
| 14 | 58 | F | 2.11 | Intolerant | 46,XX, t(5;9;22)(q35;q34;q11) [15]/ 46XX [5] |
| 15 | 65 | M | 1.2 | Resistant | 46,XY, t(9;22)(q34;q11) [22] |
| 16 | 54 | F | 9.11 | Resistant | 46,XX, t(9;22)(q34;q11) [17] |
| 17 | 53 | F | 2.8 | Resistant | 46,XX, t(9;22)(q34;q11) [20] |
| 18 | 38 | M | 6.2 | Resistant | 46,XY, t(9;22)(q34;q11) [20] |
| 19 | 69 | M | 1.3 | Resistant | 46,XY, t(9;22)(q34;q11) [20] |
| Patient no. . | Age, y . | Sex . | Disease duration, y . | IFN status . | Karyotype [no. metaphases] . |
|---|---|---|---|---|---|
| 1 | 46 | F | 4.1 | Resistant | 46,XX, t(22;9)(9;1)(q11;q34-q32;q42) [18] |
| 2 | 19 | F | 3.7 | Resistant | 46,XX, t(9;22)(q34;q11)[17]/ 46,XX [9] |
| 3 | 54 | F | 1.6 | Intolerant | 46,XX, t(9;22)(q34;q11) [20] |
| 4 | 66 | M | 2.5 | Intolerant | 46,XY, t(9;22)(q34;q11) [20] |
| 5 | 60 | F | 4.2 | Resistant | 46,XX, t(9;22)(q34;q11) [19]/ 46,XX [1] |
| 6 | 51 | F | 1.8 | Intolerant | 46,XX, t(9;22)(q34;q11) [17]/ 46,XX [3] |
| 7 | 69 | M | 3.9 | Resistant | 46,XY, t(9;22)(q34;q11) [21] |
| 8 | 65 | M | 7.3 | Resistant | 46,XY, t(9;22)(q34;q11) [15] |
| 9 | 70 | M | 6.5 | Intolerant | 46,XY, t(9;22)(q34;q11)[23]/ 46XY [2] |
| 10 | 60 | F | 1.7 | Resistant | 46,XX, t(7;8)(q22;q13), t(9;22)(q34;q11) [15]/ 46,XX, t(9;22)(q34;q11) [5]/ 46,XX [1] |
| 11 | 52 | M | 1.1 | Resistant/Intolerant | 46,XY, t(9;22)(q34;q11) [21] |
| 12 | 64 | M | 3.9 | Resistant | 46,XY, t(22;9)(9;13;1)(q11;q34;q32;q21;q31) [19]/ 47,XY, t(22;9)(9;13;1)(q11;q34;q32;q21;q31),+ 8 [1] |
| 13 | 69 | F | 1.5 | Resistant | 46,XX, t(9;22)(q34;q11) [20] |
| 14 | 58 | F | 2.11 | Intolerant | 46,XX, t(5;9;22)(q35;q34;q11) [15]/ 46XX [5] |
| 15 | 65 | M | 1.2 | Resistant | 46,XY, t(9;22)(q34;q11) [22] |
| 16 | 54 | F | 9.11 | Resistant | 46,XX, t(9;22)(q34;q11) [17] |
| 17 | 53 | F | 2.8 | Resistant | 46,XX, t(9;22)(q34;q11) [20] |
| 18 | 38 | M | 6.2 | Resistant | 46,XY, t(9;22)(q34;q11) [20] |
| 19 | 69 | M | 1.3 | Resistant | 46,XY, t(9;22)(q34;q11) [20] |
IFN indicates interferon alfa.